Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Adjuvant Therapy in Resected PD-L1 Positive NSCLC
CTR20170158Phase 3Active
- Sponsor
- MedImmune
- Start
- May 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started May 2017; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170158.